Seborrheic Dermatitis
Results reported from phase III studies of Sebazole
Published in Medical Letter on the CDC and FDA, February 15th, 2004
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by a red, scaly, itchy rash primarily occurring on the face, scalp, hairline, eyebrows, and trunk. Results determined that Sebazole is effective in the treatment of facial seborrheic dermatitis with a once-daily treatment regimen of only 2 weeks.
The two blinded placebo controlled phase III trials enrolled more than 900 patients in approximately 50 centers in the United States and Europe. Each study compared the safety and efficacy of the following treatment arms: Sebazole...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Meningitis
Echovirus type 13 emerging as prominent enterovirus - Adolescent Health
Survey finds 8,000 clandestine abortions occur yearly in Burkina Faso capital - Alzheimer Disease
Namenda now available nationwide - Amyotrophic Lateral Sclerosis
AEOL 10150 clears toxicology hurdle; company makes initial draw on financing - Animal Models
Diets with different levels of soy affect toxicity assessments in rats - Anticancer Therapy
Recent developments in antitumor taxoids reviewed - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
